Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01279
|
|||||
| Drug Name |
Phenprocoumon
|
|||||
| Synonyms |
2-hydroxy-3-(1-phenylpropyl)chromen-4-one; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one; Falithiom; Falithrom; Falithrom (TN); Fencumar; Fenprocoumona; Fenprocoumona [INN-Spanish]; Fenprocumon; Fenprocumone; Fenprocumone [DCIT]; Hexal Brand of Phenprocoumon; Liquamar; Liquamar (TN); Marcoumar; Marcoumar (TN); Marcumar; Marcumar (TN); Marcuphen; Phenprocoumalol; Phenprocoumarol; Phenprocoumarole; Phenprocoumon (USAN/INN); Phenprocoumon [USAN:INN:BAN]; Phenprocoumone; Phenprocoumone [INN-French]; Phenprocoumonum; Phenprocoumonum [INN-Latin]; Phenprocumone; Phenprocumonum; Phenprogramma; Phenylpropylhydroxycumarinum; Ro 1-4849; Roche Brand of Phenprocoumon; U29342; Worwag Brand of Phenprocoumon
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Thrombosis [ICD11:BD71.4, BD72] | Approved | [1] | |||
| Pulmonary embolism [ICD11:BB00] | Approved | [1] | ||||
| Therapeutic Class |
Anticoagulants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H16O3
|
|||||
| Canonical SMILES |
CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
|
|||||
| InChI |
InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
|
|||||
| InChIKey |
DQDAYGNAKTZFIW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 435-97-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 280.3 | Topological Polar Surface Area | 46.5 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
612021
,7845703
,7980293
,8030662
,10522853
,14848717
,29228465
,42684251
,46506423
,47207126
,47815891
,48416418
,49956264
,56394971
,57309600
,57325861
,76965160
,93302774
,103179879
,103950577
,104253508
,104321863
,106673762
,125823525
,126658557
,127770897
,134338056
,134974499
,135692445
,137126448
,137239431
,142971044
,160964285
,162011455
,162224643
,162652374
,163418248
,164042860
,174529392
,176262013
,178103445
,179326620
,184545898
,186014484
,198993025
,219400682
,223670210
,223705291
,226427577
,227840593
|
|||||
| ChEBI ID |
ChEBI:50438
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Phenprocoumon was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):259-65. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.